Search

everythinglearnresearchcommunity

for

Search:↓

Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.

Women with PCOS have higher levels of AMH in their blood and follicles, and this can help predict their risk of overreaction to fertility treatments.

Hormones affect skin aging and fat distribution, and treatments can help, but only minoxidil is proven for female hair loss.

Anti-Müllerian hormone is a specific marker for ovarian issues in women with conditions like PCOS.

Testosterone therapy may improve mood, well-being, and sexual function in premenopausal women, but more research is needed on its long-term safety and effectiveness.

High levels of anti-Müllerian hormone can indicate polycystic ovarian syndrome in women who can have babies.

The document concludes that managing health issues like menopause, cardiovascular risk, and hair loss is crucial for promoting longevity in aging women.

Women with prediabetes may have a higher risk of PCOS-like changes, especially if they have impaired glucose tolerance.

ADAM17 could be a potential target for treating PCOS.

PCOS, aging, and fertility are linked by hormonal and metabolic issues, with lifestyle changes and treatments offering potential help.

Steroid-producing capabilities in certain cancers may contribute to treatment resistance.

Chemotherapy significantly lowers Inhibin A levels in breast cancer patients.

The guide recommends specific methods for diagnosing PCOS and various treatments for its symptoms, while considering the health impacts on adolescents.

Testosterone replacement may help some postmenopausal women with symptoms like fatigue and low libido, but more research is needed to fully understand its effects.

Amenorrhea is relatively rare and initial testing should check FSH, TSH, and prolactin levels.

The current methods for diagnosing polycystic ovary syndrome are too vague and may lead to misdiagnosis and problems in research.

SHBG may be a useful early indicator and treatment target for PCOS.

The document concludes that identifying the cause of amenorrhea is crucial for proper treatment.

New treatments for PCOS show promise, but no current medication treats all aspects of the condition.

PRP treatment can safely boost hormone levels in some IVF patients with low ovarian reserve.

Diagnosing PCOS in teenagers is hard because its symptoms often look like normal puberty, and there's a need for better diagnosis methods and agreement on criteria.

Amenorrhea is when a woman doesn't have periods, with primary amenorrhea starting by age 15 or within five years of breast development, and secondary amenorrhea when periods stop for three months. It affects 3-4% of women not pregnant, breastfeeding, or in menopause, mainly due to polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and ovarian failure.

Injecting platelet-derived growth factors into ovaries may improve IVF outcomes by enhancing egg quality and embryo health.

Amenorrhea, or the absence of periods, should be evaluated by age 15 or within five years of early breast development, and is most commonly caused by conditions like polycystic ovary syndrome and hypothalamic amenorrhea.

Effective hirsutism management requires identifying the cause, combining new and traditional treatments, and setting realistic expectations for patients.

High doses of nandrolone decanoate disrupt ovarian hormones and receptors in rats, with recovery only at lower doses and longer recovery times.

The document concludes that managing female hyperandrogenism requires a combination of identifying the cause, lifestyle changes, medication, and cosmetic treatments.

Flutamide, an antiandrogen, has minimal impact on female rat endocrine systems and does not significantly change their reproductive cycles.

New ultrasound criteria for diagnosing PCOS in North African patients were successfully established.

The hairless gene is crucial for hair health, and its mutations cause hair loss.